0001209191-23-049809.txt : 20230918
0001209191-23-049809.hdr.sgml : 20230918
20230918181351
ACCESSION NUMBER: 0001209191-23-049809
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230914
FILED AS OF DATE: 20230918
DATE AS OF CHANGE: 20230918
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LOUMEAU ERIC J
CENTRAL INDEX KEY: 0001239648
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37985
FILM NUMBER: 231262075
MAIL ADDRESS:
STREET 1: C/O HOLLIS-EDEN PHARMACEUTICALS
STREET 2: 4435 EASTGATE MALL STE.400
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANAPTYSBIO, INC
CENTRAL INDEX KEY: 0001370053
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203828755
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-362-6295
MAIL ADDRESS:
STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYSBIO INC
DATE OF NAME CHANGE: 20080828
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC
DATE OF NAME CHANGE: 20060724
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-09-14
0
0001370053
ANAPTYSBIO, INC
ANAB
0001239648
LOUMEAU ERIC J
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO
CA
92121
0
1
0
0
Chief Legal Officer
0
Common Stock
2023-09-14
4
M
0
6000
A
6882
D
Common Stock
2023-09-14
4
S
0
2105
19.48
D
4777
D
Common Stock
2023-09-18
4
S
0
3895
19.3151
D
882
D
Restricted Stock Unit
2023-09-14
4
M
0
6000
0.00
D
Common Stock
6000
6000
D
Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
Reflects the acquisition of 882 shares acquired under the Company's ESPP.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.135 to $19.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Eric Loumeau
2023-09-18